{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:49:25Z","timestamp":1789001365638,"version":"build-2803163510"},"reference-count":134,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.autrev.2021.102945","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T12:04:15Z","timestamp":1631189055000},"page":"102945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The mosaic of autoimmunity - A taste for more. The 12th international congress of autoimmunity 2021 (AUTO12) virtual"],"prefix":"10.1016","volume":"20","author":[{"given":"Naim","family":"Mahroum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdi","family":"Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noy","family":"Lavine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviran","family":"Ohayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Amital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.autrev.2021.102945_bb0005","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.autrev.2017.07.022","article-title":"Cancer and autoimmune diseases","volume":"16","author":"Giat","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0010","doi-asserted-by":"crossref","first-page":"102469","DOI":"10.1016\/j.autrev.2020.102469","article-title":"Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: a comprehensive review","volume":"19","author":"Lee","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2021.102945_bb0015","first-page":"645","article-title":"Updates in rheumatology and autoimmunity in the Israel Medical Association Journal (IMAJ) 2018","volume":"20","author":"Toubi","year":"2018","journal-title":"Isr Med Assoc J"},{"issue":"22","key":"10.1016\/j.autrev.2021.102945_bb0020","first-page":"717","article-title":"Highlights in autoimmunity: 2020","volume":"11","author":"Toubi","year":"2020","journal-title":"Isr Med Assoc J"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/00039896.1994.9940373","article-title":"Silicone breast implants and autoimmunity: causation or myth?","volume":"49","author":"Brautbar","year":"1994","journal-title":"Arch Environ Health"},{"key":"10.1016\/j.autrev.2021.102945_bb0030","doi-asserted-by":"crossref","first-page":"587380","DOI":"10.3389\/fimmu.2020.587380","article-title":"Epstein-Barr virus and systemic autoimmune diseases","volume":"11","author":"Houen","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0035","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.autrev.2018.12.010","article-title":"Emerging role of air pollution in autoimmune diseases","volume":"18","author":"Zhao","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102945_bb0040","doi-asserted-by":"crossref","first-page":"100051","DOI":"10.1016\/j.jtauto.2020.100051","article-title":"Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity","volume":"3","author":"Lyons-Weiler","year":"2020","journal-title":"J Transl Autoimmun"},{"issue":"17","key":"10.1016\/j.autrev.2021.102945_bb0045","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.12998\/wjcc.v8.i17.3621","article-title":"Autoimmunity as the comet tail of COVID-19 pandemic","volume":"8","author":"Talotta","year":"2020","journal-title":"World J Clin Cases"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.it.2020.11.003","article-title":"Combining antivirals and immunomodulators to fight COVID-19","volume":"42","author":"Feuillet","year":"2021","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/infdis\/jiaa717","article-title":"The effect of IL-6 inhibitors on mortality among hospitalized COVID-19 patients: a multicenter study","volume":"223","author":"Sinha","year":"2021","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12026-016-8817-7","article-title":"HLA-DRB1 the notorious gene in the mosaic of autoimmunity","volume":"65","author":"Arango","year":"2017","journal-title":"Immunol Res"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0065","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2021.102945_bb0070","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/ng.3143","article-title":"Variation at HLA-DRB1 is associated with resistance to enteric fever","volume":"46","author":"Dunstan","year":"2014","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0075","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/ije\/dyy217","article-title":"Silicone breast implants and the risk of autoimmune\/rheumatic disorders: a real-world analysis","volume":"47","author":"Watad","year":"2018","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaut.2010.07.003","article-title":"\u2018ASIA\u2019 - autoimmune\/inflammatory syndrome induced by adjuvants","volume":"36","author":"Shoenfeld","year":"2011","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0085","first-page":"380","article-title":"The dark side of beauty: about breast implants and lymphoma","volume":"19","author":"Versini","year":"2017","journal-title":"Isr Med Assoc J"},{"issue":"8","key":"10.1016\/j.autrev.2021.102945_bb0090","first-page":"517","article-title":"Hyperstimulation of adaptive immunity as the common pathway for silicone breast implants, autoimmunity, and lymphoma of the breast","volume":"21","author":"Watad","year":"2019","journal-title":"Isr Med Assoc J"},{"issue":"7","key":"10.1016\/j.autrev.2021.102945_bb0095","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.4049\/jimmunol.1600242","article-title":"Role of metabolism in the immunobiology of regulatory T cells","volume":"197","author":"Galgani","year":"2016","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102945_bb0100","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.autrev.2017.08.001","article-title":"The Yin and Yang of regulatory T cell and therapy progress in autoimmune disease","volume":"16","author":"Qiao","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102945_bb0105","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3389\/fimmu.2019.03136","article-title":"Molecular mechanisms controlling Foxp3 expression in health and autoimmunity: from epigenetic to post-translational regulation","volume":"10","author":"Colamatteo","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102945_bb0110","doi-asserted-by":"crossref","first-page":"102715","DOI":"10.1016\/j.autrev.2020.102715","article-title":"Regulatory T cell heterogeneity and therapy in autoimmune diseases","volume":"20","author":"Zhang","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0115","doi-asserted-by":"crossref","first-page":"102526","DOI":"10.1016\/j.autrev.2020.102526","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: a systematic review","volume":"19","author":"Park","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010055","article-title":"DNA damage response and oxidative stress in systemic autoimmunity","volume":"21","author":"Souliotis","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2021.102945_bb0125","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3389\/fimmu.2020.01322","article-title":"PIK3AP1 and SPON2 genes are differentially methylated in patients with Periodic Fever, aphthous Stomatitis, Pharyngitis, and Adenitis (PFAPA) syndrome","volume":"11","author":"Lovsin","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102945_bb0130","doi-asserted-by":"crossref","first-page":"102646","DOI":"10.1016\/j.autrev.2020.102646","article-title":"Update on IgG4-mediated autoimmune diseases: new insights and new family members","volume":"19","author":"Koneczny","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102945_bb0135","doi-asserted-by":"crossref","first-page":"605214","DOI":"10.3389\/fimmu.2020.605214","article-title":"Common denominators in the immunobiology of IgG4 autoimmune diseases: what do glomerulonephritis, pemphigus vulgaris, myasthenia gravis, thrombotic thrombocytopenic purpura and autoimmune encephalitis have in common?","volume":"11","author":"Koneczny","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102945_bb0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1134\/S0026893317020030","article-title":"Allergy and autoimmunity: molecular diagnostics, therapy, and presumable pathogenesis","volume":"51","author":"Arefieva","year":"2017","journal-title":"Mol Biol (Mosk)"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0145","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.autrev.2008.09.004","article-title":"Allergy and autoimmunity: parallels and dissimilarity: the yin and yang of immunopathology","volume":"8","author":"Bartunkova","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2021.102945_bb0150","doi-asserted-by":"crossref","first-page":"102845","DOI":"10.1016\/j.autrev.2021.102845","article-title":"Hygiene hypothesis and autoimmune diseases: a narrative review of clinical evidences and mechanisms","volume":"20","author":"Murdaca","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0155","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3899\/jrheum.090492","article-title":"Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis","volume":"37","author":"Matsuyama","year":"2010","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102945_bb0160","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2310\/JIM.0b013e31828deed2","article-title":"Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor","volume":"61","author":"Li","year":"2013","journal-title":"J Invest Med"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0165","doi-asserted-by":"crossref","first-page":"102756","DOI":"10.1016\/j.autrev.2021.102756","article-title":"Pathophysiologic role of Interleukin-33\/ST2 in Sjogren\u2019s syndrome","volume":"20","author":"Soyfoo","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2021.102945_bb0170","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/ard.2009.122655","article-title":"IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy","volume":"69","author":"Verri","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2021.102945_bb0175","doi-asserted-by":"crossref","first-page":"102732","DOI":"10.1016\/j.autrev.2020.102732","article-title":"Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: a study of 12 patients and a literature review","volume":"20","author":"Liozon","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0180","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/BOR.0000000000000391","article-title":"Silicone breast implants and autoimmune rheumatic diseases: myth or reality","volume":"29","author":"Cohen Tervaert","year":"2017","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0185","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.berh.2019.01.003","article-title":"Autoinflammatory\/autoimmunity syndrome induced by adjuvants (Shoenfeld\u2019s syndrome) in patients after a polypropylene mesh implantation","volume":"32","author":"Cohen Tervaert","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2021.102945_bb0190","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.autrev.2018.07.003","article-title":"Autoinflammatory\/autoimmunity syndrome induced by adjuvants (ASIA; Shoenfeld\u2019s syndrome): a new flame","volume":"17","author":"Cohen Tervaert","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0195","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0971-4065.159303","article-title":"Th1, Th2 and Treg\/T17 cytokines in two types of proliferative glomerulonephritis","volume":"26","author":"Stangou","year":"2016","journal-title":"Ind J Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102945_bb0200","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.autrev.2018.08.006","article-title":"Th17 cells in renal inflammation and autoimmunity","volume":"18","author":"Dolff","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102945_bb0205","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3389\/fimmu.2019.02221","article-title":"CD27(+)CD38(hi) B cell frequency during remission predicts relapsing disease in granulomatosis with polyangiitis patients","volume":"10","author":"von Borstel","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/2175-8239-jbn-2018-0254","article-title":"Rituximab use in adult glomerulopathies and its rationale","volume":"42","author":"Santos","year":"2020","journal-title":"J Bras Nefrol"},{"key":"10.1016\/j.autrev.2021.102945_bb0215","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1038\/ncomms16021","article-title":"Transancestral mapping and genetic load in systemic lupus erythematosus","volume":"8","author":"Langefeld","year":"2017","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.autrev.2021.102945_bb0220","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41584-020-0472-7","article-title":"The (Orf)ull truth about IRF5 and type I interferons in SLE","volume":"16","author":"Elkon","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102945_bb0225","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/rheumatology\/kez655","article-title":"The impact of long-term biologics\/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis","volume":"59","author":"Chen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0230","doi-asserted-by":"crossref","first-page":"102776","DOI":"10.1016\/j.autrev.2021.102776","article-title":"Rheumatoid arthritis: extra-articular manifestations and comorbidities","volume":"20","author":"Figus","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0235","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/acr.23875","article-title":"Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"72","author":"Singh","year":"2020","journal-title":"Arthrit Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.autrev.2021.102945_bb0240","doi-asserted-by":"crossref","first-page":"102684","DOI":"10.1016\/j.autrev.2020.102684","article-title":"Parkinson\u2019s disease is an autoimmune disease: a reappraisal","volume":"19","author":"Bonam","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102945_bb0245","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.schres.2018.06.033","article-title":"Autoimmune diseases are associated with an increased risk of schizophrenia: a nationwide population-based cohort study","volume":"202","author":"Wang","year":"2018","journal-title":"Schizophr Res"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0250","doi-asserted-by":"crossref","first-page":"102780","DOI":"10.1016\/j.autrev.2021.102780","article-title":"Neuropsychiatric involvement in systemic lupus erythematosus: a review","volume":"20","author":"Carrion-Barbera","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0255","doi-asserted-by":"crossref","first-page":"102792","DOI":"10.1016\/j.autrev.2021.102792","article-title":"The SARS-CoV-2 as an instrumental trigger of autoimmunity","volume":"20","author":"Dotan","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2021.102945_bb0260","doi-asserted-by":"crossref","first-page":"102899","DOI":"10.1016\/j.autrev.2021.102899","article-title":"Similarities between COVID-19 and systemic sclerosis early vasculopathy: a \u201cviral\u201d challenge for future research in scleroderma","volume":"20","author":"Matucci-Cerinic","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2021.102945_bb0265","doi-asserted-by":"crossref","first-page":"102883","DOI":"10.1016\/j.autrev.2021.102883","article-title":"Rheumatological complications of Covid 19","volume":"20","author":"Zacharias","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2021.102945_bb0270","doi-asserted-by":"crossref","first-page":"102597","DOI":"10.1016\/j.autrev.2020.102597","article-title":"Covid-19 and autoimmunity","volume":"19","author":"Ehrenfeld","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2021.102945_bb0275","doi-asserted-by":"crossref","first-page":"102840","DOI":"10.1016\/j.autrev.2021.102840","article-title":"Serological cross-reactivity between viruses and their contribution to autoimmunity","volume":"20","author":"Vojdani","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2021.102945_bb0280","doi-asserted-by":"crossref","first-page":"102909","DOI":"10.1016\/j.autrev.2021.102909","article-title":"The mechanism behind flaring\/triggering of autoimmunity disorders associated with COVID-19","volume":"20","author":"Redwan","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0285","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.7150\/ijbs.59547","article-title":"Hydroxychloroquine\/chloroquine as therapeutics for COVID-19: truth under the mystery","volume":"17","author":"Chen","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.autrev.2021.102945_bb0290","doi-asserted-by":"crossref","first-page":"102135","DOI":"10.1016\/j.tmaid.2021.102135","article-title":"Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis","volume":"43","author":"Chivese","year":"2021","journal-title":"Travel Med Infect Dis"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009448","article-title":"Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity","volume":"17","author":"Bozzano","year":"2021","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0300","doi-asserted-by":"crossref","first-page":"102754","DOI":"10.1016\/j.autrev.2021.102754","article-title":"Autoantibodies in COVID-19: frequency and function","volume":"20","author":"Gao","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102945_bb0305","doi-asserted-by":"crossref","first-page":"100091","DOI":"10.1016\/j.jtauto.2021.100091","article-title":"Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19","volume":"4","author":"Anaya","year":"2021","journal-title":"J Transl Autoimmun"},{"issue":"8","key":"10.1016\/j.autrev.2021.102945_bb0310","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jiph.2021.06.004","article-title":"Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"14","author":"Pinzon","year":"2021","journal-title":"J Infect Public Health"},{"issue":"2","key":"10.1016\/j.autrev.2021.102945_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30422-7","article-title":"Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study","volume":"3","author":"Jorge","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0320","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0325","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/art.1780240107","article-title":"Prednisone and azathioprine for polymyositis: long-term followup","volume":"24","author":"Bunch","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0330","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.berh.2017.09.013","article-title":"A review on SLE and malignancy","volume":"31","author":"Choi","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2021.102945_bb0335","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1093\/rheumatology\/keaa188","article-title":"Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus","volume":"59","author":"Kedves","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2021.102945_bb0340","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3201\/eid2505.181591","article-title":"Severe myasthenic manifestation of leptospirosis associated with new sequence type of Leptospira interrogans","volume":"25","author":"Tomschik","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.autrev.2021.102945_bb0345","first-page":"1","article-title":"Human parvovirus B19 infection in rheumatoid arthritis patients: screening and clinical significance","volume":"25","author":"Aboelazm","year":"2018","journal-title":"Egypt J Immunol"},{"issue":"14","key":"10.1016\/j.autrev.2021.102945_bb0350","doi-asserted-by":"crossref","first-page":"8227","DOI":"10.1073\/pnas.95.14.8227","article-title":"Human parvovirus B19 as a causative agent for rheumatoid arthritis","volume":"95","author":"Takahashi","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0355","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1007\/s00415-013-6912-4","article-title":"Cytomegalovirus and multiple sclerosis risk","volume":"260","author":"Pakpoor","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2021.102945_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2019.03.007","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: insights from an analysis of 500 cases","volume":"203","author":"Watad","year":"2019","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102945_bb0365","article-title":"Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination","volume":"9","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"9396","key":"10.1016\/j.autrev.2021.102945_bb0370","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(03)14802-7","article-title":"Vaccination and autoimmune disease: what is the evidence?","volume":"362","author":"Wraith","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.autrev.2021.102945_bb0375","first-page":"589","article-title":"Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy","volume":"19","author":"Kanakoudi-Tsakalidou","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102945_bb0380","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MPG.0b013e3181bab351","article-title":"Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy","volume":"50","author":"Lu","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0385","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13317-020-0127-3","article-title":"The perspective on standardisation and harmonisation: the viewpoint of the EASI president","volume":"11","author":"Damoiseaux","year":"2020","journal-title":"Auto Immun Highlights"},{"issue":"5","key":"10.1016\/j.autrev.2021.102945_bb0390","doi-asserted-by":"crossref","first-page":"102508","DOI":"10.1016\/j.autrev.2020.102508","article-title":"Precision health: a pragmatic approach to understanding and addressing key factors in autoimmune diseases","volume":"19","author":"Conrad","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2021.102945_bb0395","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1136\/annrheumdis-2019-215845","article-title":"A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation","volume":"78","author":"Fox","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2021.102945_bb0400","doi-asserted-by":"crossref","first-page":"102743","DOI":"10.1016\/j.autrev.2020.102743","article-title":"An updated advance of autoantibodies in autoimmune diseases","volume":"20","author":"Xiao","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2021.102945_bb0405","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.autrev.2009.01.013","article-title":"Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory","volume":"8","author":"Bossuyt","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102945_bb0410","doi-asserted-by":"crossref","first-page":"655262","DOI":"10.3389\/fimmu.2021.655262","article-title":"Likelihood ratio approach and clinical interpretation of laboratory tests","volume":"12","author":"Fierz","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102945_bb0415","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2017-212365","article-title":"Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR\/EULAR classification of rheumatoid arthritis","volume":"77","author":"Van Hoovels","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2021.102945_bb0420","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/rheumatology\/kex266","article-title":"A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibodies","volume":"56","author":"Bossuyt","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.autrev.2021.102945_bb0425","doi-asserted-by":"crossref","first-page":"102386","DOI":"10.1016\/j.autrev.2019.102386","article-title":"Harmonization of clinical interpretation of antinuclear antibody test results by solid phase assay and by indirect immunofluorescence through likelihood ratios","volume":"18","author":"Bossuyt","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2021.102945_bb0430","doi-asserted-by":"crossref","first-page":"102635","DOI":"10.1016\/j.autrev.2020.102635","article-title":"Assigning likelihood ratios to immunoblot assay results: a clinical approach in autoimmune reporting","volume":"19","author":"Infantino","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2021.102945_bb0435","doi-asserted-by":"crossref","first-page":"102400","DOI":"10.1016\/j.autrev.2019.102400","article-title":"ANA as an entry criterion for the classification of SLE","volume":"18","author":"Pisetsky","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102945_bb0440","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","article-title":"Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014\u20132015","volume":"6","author":"Chan","year":"2015","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102945_bb0445","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2020-1178","article-title":"Harmonization of antineutrophil cytoplasmic antibodies (ANCA) testing by reporting test result-specific likelihood ratios: position paper","volume":"59","author":"Bossuyt","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"9634","key":"10.1016\/j.autrev.2021.102945_bb0450","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0455","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0460","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/BOR.0000000000000004","article-title":"Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies","volume":"26","author":"Clifford","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0465","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0470","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40037","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of takayasu arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0475","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.24200","article-title":"Ustekinumab for the treatment of giant cell arteritis","volume":"73","author":"Matza","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0480","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","article-title":"Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis","volume":"50","author":"Nesher","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2021.102945_bb0485","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1002\/art.22141","article-title":"Antiplatelet and anticoagulant therapy in patients with giant cell arteritis","volume":"54","author":"Lee","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2021.102945_bb0490","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.autrev.2019.06.003","article-title":"Survival of patient with giant cell arteritis: impact of vision loss and treatment with aspirin","volume":"18","author":"Nesher","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2021.102945_bb0495","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.autrev.2014.02.006","article-title":"Effect of antiplatelet\/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis","volume":"13","author":"Martinez-Taboada","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0500","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1253\/circj.CJ-09-0905","article-title":"Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis","volume":"74","author":"de Souza","year":"2010","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0505","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2021.102945_bb0510","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/kez630","article-title":"Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study","volume":"59","author":"Nakaoka","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0515","doi-asserted-by":"crossref","first-page":"102829","DOI":"10.1016\/j.autrev.2021.102829","article-title":"Vasculitis therapy refines vasculitis mechanistic classification","volume":"20","author":"Torp","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2021.102945_bb0520","article-title":"Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients","volume":"4","author":"Regola","year":"2020","journal-title":"Rheumatol Adv Pract"},{"issue":"10031","key":"10.1016\/j.autrev.2021.102945_bb0525","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.autrev.2021.102945_bb0530","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3899\/jrheum.190927","article-title":"Mortality among patients with giant cell arteritis: a large-scale population-based cohort study","volume":"47","author":"Ben-Shabat","year":"2020","journal-title":"J Rheumatol"},{"issue":"25","key":"10.1016\/j.autrev.2021.102945_bb0535","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2021.102945_bb0540","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in Treg cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102945_bb0545","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2021.102945_bb0550","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fimmu.2018.01169","article-title":"Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and neuromyelitis optica from preclinical to clinical trials","volume":"9","author":"Florez-Grau","year":"2018","journal-title":"Front Immunol"},{"issue":"4 Suppl 92","key":"10.1016\/j.autrev.2021.102945_bb0555","first-page":"S97","article-title":"Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells","volume":"33","author":"Suwandi","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2021.102945_bb0560","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nri2199","article-title":"Protective immune mechanisms in helminth infection","volume":"7","author":"Anthony","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0565","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nrrheum.2013.3","article-title":"Autoimmunity: will worms cure rheumatoid arthritis?","volume":"9","author":"Shor","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2021.102945_bb0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200615","article-title":"Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis","volume":"13","author":"Blank","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.autrev.2021.102945_bb0575","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.autrev.2021.102945_bb0580","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.autrev.2021.102945_bb0585","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0590","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0595","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/RHU.0000000000000290","article-title":"Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome","volume":"21","author":"Zikos","year":"2015","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2021.102945_bb0600","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/archneur.57.8.1183","article-title":"Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis","volume":"57","author":"Khoury","year":"2000","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102945_bb0605","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.autrev.2021.102945_bb0610","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.4049\/jimmunol.169.9.4712","article-title":"Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis","volume":"169","author":"Kohm","year":"2002","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102945_bb0615","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/blood-2004-09-3579","article-title":"Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes","volume":"105","author":"Mekala","year":"2005","journal-title":"Blood"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2021.102945_bb0620","first-page":"iii6","article-title":"Autoantibodies as predictors of pregnancy complications","volume":"47","author":"Carp","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0625","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.tjog.2015.09.001","article-title":"Investigation of the impact of antinuclear antibody on the outcome of in vitro fertilization\/intracytoplasmic sperm injection treatment","volume":"54","author":"Li","year":"2015","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0630","first-page":"221","article-title":"Prevalence and clinical significance of antinuclear antibodies in Iranian women with unexplained recurrent miscarriage","volume":"12","author":"Molazadeh","year":"2014","journal-title":"Iran J Reprod Med"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0635","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/aji.12373","article-title":"Effect of prednisolone administration on patients with unexplained recurrent miscarriage and in routine intracytoplasmic sperm injection: a meta-analysis","volume":"74","author":"Dan","year":"2015","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.autrev.2021.102945_bb0640","author":"ClinicalTrials.com"},{"key":"10.1016\/j.autrev.2021.102945_bb0645","article-title":"Management of Sjogren\u2019s syndrome: present issues and future perspectives","volume":"8","author":"Vitali","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.autrev.2021.102945_bb0650","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060826","article-title":"The potential role of genomic medicine in the therapeutic management of rheumatoid arthritis","volume":"8","author":"Acosta-Herrera","year":"2019","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.autrev.2021.102945_bb0655","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40120-020-00190-8","article-title":"Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2021.102945_bb0660","first-page":"54","article-title":"The phenomenon of release activity and the hypothesis of \u201cspatial\u201d homeostasis","volume":"44","author":"Epstein","year":"2013","journal-title":"Usp Fiziol Nauk"},{"issue":"5","key":"10.1016\/j.autrev.2021.102945_bb0665","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.4049\/jimmunol.2000098","article-title":"Insights into the mechanism of action of highly diluted biologics","volume":"205","author":"Tarasov","year":"2020","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102945_bb0670","doi-asserted-by":"crossref","first-page":"22198","DOI":"10.1038\/s41598-020-78826-w","article-title":"Piezoelectric and dielectric properties of Bi3TiNbO9 prepared by hot pressing from powders activated using the serial dilution method","volume":"10","author":"Spitsin","year":"2020","journal-title":"Sci Rep"}],"updated-by":[{"DOI":"10.1016\/j.autrev.2022.103039","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000}}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:22:56Z","timestamp":1761600176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221002202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":134,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1568997221002202"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102945","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mosaic of autoimmunity - A taste for more. The 12th international congress of autoimmunity 2021 (AUTO12) virtual","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102945"}}